Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-20 6:52 pm Sale | 2025-05-16 | 13D | XOMA Corporation XOMA | BIOTECHNOLOGY VALUE FUND L P | 2,590,303 21.600% | -392,723 (-13.17%) | Filing History |
| 2025-05-19 6:42 pm Sale | 2025-05-15 | 13G | Allakos Inc. ALLK | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -16,552,417 (Position Closed) | Filing History |
| 2025-05-15 4:42 pm Purchase | 2025-03-31 | 13G | Vigil Neuroscience, Inc. VIGL | BIOTECHNOLOGY VALUE FUND L P | 4,734,500 9.990% | 1,994,773 (+72.81%) | Filing History |
| 2025-05-15 4:40 pm Purchase | 2025-03-31 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 5,263,541 9.990% | 190,538 (+3.76%) | Filing History |
| 2025-05-15 4:37 pm Purchase | 2025-03-31 | 13G | Septerna, Inc. SEPN | BIOTECHNOLOGY VALUE FUND L P | 4,396,124 9.900% | 1,944,100 (+79.29%) | Filing History |
| 2025-05-15 4:35 pm Purchase | 2025-03-31 | 13G | iTeos Therapeutics, Inc. ITOS | BIOTECHNOLOGY VALUE FUND L P | 3,075,000 8.100% | 750,000 (+32.26%) | Filing History |
| 2025-05-15 4:33 pm Purchase | 2025-03-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BIOTECHNOLOGY VALUE FUND L P | 5,660,132 9.200% | 1,266,922 (+28.84%) | Filing History |
| 2025-05-15 4:31 pm Sale | 2025-03-31 | 13G | GH Research PLC GHRS | BIOTECHNOLOGY VALUE FUND L P | 8,827,712 14.200% | -1,572,446 (-15.12%) | Filing History |
| 2025-05-15 4:29 pm Sale | 2025-03-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,632,749 9.990% | -201,548 (-4.17%) | Filing History |
| 2025-05-15 4:27 pm Sale | 2025-03-31 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 4,440,000 7.000% | -1,790,845 (-28.74%) | Filing History |
| 2025-05-15 4:25 pm Purchase | 2025-03-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 1,252,441 9.990% | 158,942 (+14.54%) | Filing History |
| 2025-05-09 5:50 pm Unchanged | 2025-05-07 | 13D | Inventiva S.A. IVA | BIOTECHNOLOGY VALUE FUND L P | 8,545,499 6.100% | 0 (Unchanged) | Filing History |
| 2025-04-16 6:49 pm Sale | 2025-04-14 | 13G | Third Harmonic Bio, Inc. THRD | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -2,372,933 (Position Closed) | Filing History |
| 2025-04-09 09:00 am Unchanged | 2025-04-09 | 13D | ESSA Pharma Inc. EPIX | BIOTECHNOLOGY VALUE FUND L P | 8,748,629 19.700% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:28 pm Purchase | 2024-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | BIOTECHNOLOGY VALUE FUND L P | 3,084,324 9.970% | 307,079 (+11.06%) | Filing History |
| 2025-02-14 4:26 pm Purchase | 2024-12-31 | 13G | Verastem, Inc. VSTM | BIOTECHNOLOGY VALUE FUND L P | 4,706,551 9.990% | 427,030 (+9.98%) | Filing History |
| 2025-02-14 4:24 pm Sale | 2024-12-31 | 13G | Tyra Biosciences, Inc. TYRA | BIOTECHNOLOGY VALUE FUND L P | 3,944,194 7.800% | -717,000 (-15.38%) | Filing History |
| 2025-02-14 4:22 pm Sale | 2024-12-31 | 13G | Ikena Oncology, Inc. IKNA | BIOTECHNOLOGY VALUE FUND L P | 4,006,564 8.300% | -762,600 (-15.99%) | Filing History |
| 2025-02-14 4:20 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,834,297 9.990% | -2,548,345 (-34.52%) | Filing History |
| 2025-02-14 4:11 pm Purchase | 2024-12-31 | 13G | Forte Biosciences, Inc. FBRX | BIOTECHNOLOGY VALUE FUND L P | 643,622 9.990% | 643,622 (New Position) | Filing History |